PepGen Ltd (PEPG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.85 (-4.04%), Market cap $0.11B, 52-week low–high $1.01 ~ $7.17.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for PepGen Ltd are updated in real time on BlackAll Trade.
PepGen Ltd trades at $2.85 (-4.04%). Real-time quotes and charts are available on BlackAll Trade.
PepGen Ltd has a market cap of about $0.11B.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages i